Corporate Communications:
Dr. Lise Hébert
(450) 680-4500
Toll free (877) 680-4500

If you need additional assistance or information regarding the company, please send an Email to: webinfo@neurochem.com.

November 24, 1999

- Neurochem Inc. Announces Strategic Alliance Targeting Alzeimer's Disease.

Neurochem Inc. (TSX : NRM) has signed a research and development agreement in the field of neurological therapeutics with H.Lundbeck A/S, a leading Danish pharmaceutical company focused on diseases ...

October 13, 1999

- Neurochem Inc. Receives Orphan Drug Status from FDA for Fibrillex™.

Neurochem Inc. (TSX : NRM) has received "Orphan Drug Designation" status from the U.S. Food and Drug Administration (FDA) for Fibrillex™, a drug under development for ...

July 27, 1999

- Neurochem Inc. and Resolution Pharmaceuticals Inc. to Collaborate on Diagnosis of Alzheimer's Disease (Neuroimaging) and other Amyloid Disorders.

Neurochem Inc. (TSX : NRM) announced today the signing of an agreement to develop new radioimaging diagnostic agents targeted at amyloid deposits ...

Our site is best viewed with IE4+ at a resolution of 1024×768.
All contents copyright © 1998-2007 Neurochem Inc.
Terms, Conditions and Legal Notice.